Infection with hepatitis C virus （HCV） affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care （SOC...Infection with hepatitis C virus （HCV） affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care （SOC） involving pegylated interferon-（] （PEG-IFN a） plus ribavirin （RBV） for 48 weeks results in a sustained virologic re- sponse in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C （STAT-C） and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.展开更多
基金Project partially supported by the Centers for Oceans and Human Health Program of the National Institute of Environmental Health Sciences (No.P50ES012740)the National Science Foundation of USA (Nos.OCE04-32479 and OCE09-11000)the National Mega Project on Major Drug Development of China (No.2011ZX09401-302)
文摘Infection with hepatitis C virus （HCV） affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care （SOC） involving pegylated interferon-（] （PEG-IFN a） plus ribavirin （RBV） for 48 weeks results in a sustained virologic re- sponse in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C （STAT-C） and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.
